Mindblown: a blog about philosophy.
-

Viking Therapeutics’ Weight-Loss Drug Shows Substantial Promise
Even weekly weight loss injections can become difficult to fit into everyday life. New results from Viking Therapeutics may solve that problem.
-

Berkshire Hathaway Is Buying Lennar Stock. Why Now?
The broad pressure on homebuilders makes Lennar’s struggles part of a larger industry story rather than an isolated problem.
-

Home Depot: Why This Out-of-Favor Stock Could Surprise Investors
While Home Depot has struggled amid a weak economic environment, a rare quant signal could be the saving grace for HD stock options traders.
-

Walt Disney: Theme Parks Keep the Magic Alive, But Is DIS a Buy?
Disney presents a compelling bull case stemming from its theme park business, but that growth may not be enough to make DIS stock a Buy.
-

AutoZone Q4 Earnings: AZO Is Spending Big To Keep The Old-Car Trade Alive
AutoZone is still getting paid to keep America’s cars alive, but the company has to prove that its spending shows up in the stock price.
-

Tokenization Of Stocks: Volatility And 3 Stocks Building The New Market
Tokenization is a regulatory test of what happens when stocks move onto rails that can operate around the clock.
-

Sandisk’s AI Opportunity Could Push the Stock Above $2,000
If NAND is truly evolving from a commodity into a critical AI component, Sandisk may have an opportunity to grow into its lofty expectations
-

Royal Caribbean (RCL) Stock Offers an Intriguing Growth Trade
While options trading is always a risky proposition, the math undergirding RCL stock makes for an intriguing opportunity.
-

2 Pharmaceutical Stocks Positioned for the Next Growth Cycle
For investors willing to look past the GLP-1 spotlight, MRK and ABBV offer exposure to the next chapter in pharmaceutical stocks,
Got any book recommendations?
